ADAM 8 as a novel target for doxorubicin delivery to TNBC cells using magnetic thermosensitive liposomes

Alawak, Mohamad; Dayyih, Alice Abu; Mahmoud, Gihan; Tariq, Imran; Duse, Lili; Goergen, Nathalie; Engelhardt, Konrad; Pinnapireddy, Shashank Reddy; Jedelská, Jarmila; Awak, Muhannad; König, Alexander; Brüßler, Jana; Bartsch, Jörg W.

doi:10.1016/j.ejpb.2020.12.012

Cited by 23 publications

(12 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the release of the drugs was accelerated significantly when the temperature was increased to 40 °C, being above the lipid T m . These values align with our previous study that reported the ability of TSL to release more than 40% of its content in 30 min at 40 °C . At this temperature, the lipid bilayer is transformed from the solid gel assembled phase to a liquid disassembled phase, increasing the liposomal lipid bilayer permeability and fluidity.…”

Section: Resultsmentioning

confidence: 99%

“…These values align with our previous study that reported the ability of TSL to release more than 40% of its content in 30 min at 40 °C. 56 At this temperature, the lipid bilayer is transformed from the solid gel assembled phase to a liquid disassembled phase, increasing the liposomal lipid bilayer permeability and fluidity. This leads to the temperature-triggered release of the loaded hydrophilic and hydrophobic drugs.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Thermosensitive Liposomes Encapsulating Nedaplatin and Picoplatin Demonstrate Enhanced Cytotoxicity against Breast Cancer Cells

et al. 2022

Self Cite

View full text Add to dashboard Cite

Thermosensitive liposomes (TSL) have been used for localized temperature-responsive release of chemotherapeutics into solid cancers, with a minimum of one invention currently in clinical trials (phase III). In this study, TSL was designed using a lipid blend comprising 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG-2000) (molar ratio of 88:9:2.8:0.2). Either nedaplatin (ND) or p-sulfonatocalix[4]arene-nedaplatin was encapsulated in the aqueous inner layer of TSL to form (ND-TSL) or p-SC4-ND-TSL, respectively. The hydrophobic platinum-based drug picoplatin (P) was loaded into the external lipid bilayer of the TSL to develop P-TSL. The three nanosystems were studied in terms of size, PDI, surface charge, and on-shelf stability. Moreover, the entrapment efficiency (EE%) and release % at 37 and 40 °C were evaluated. In a 30 min in vitro release study, the maximum release of ND, p-SC4-ND, and picoplatin at 40 °C reached 74, 79, and 75%, respectively, compared to approximately 10% at 37 °C. This demonstrated temperature-triggered drug release from the TSL in all three developed systems. The designed TSL exhibited significant in vitro anticancer activity at 40 °C when tested on human mammary gland/breast adenocarcinoma cells (MDA-MB-231). The cytotoxicity of ND-TSL, p-SC4-ND-TSL, and P-TSL at 40 °C was approximately twice those observed at 37 °C. This study suggests that TSL is a promising nanoplatform for the temperaturetriggered release of platinum-based drugs into cancer cells.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Thermosensitive Liposomes Encapsulating Nedaplatin and Picoplatin Demonstrate Enhanced Cytotoxicity against Breast Cancer Cells

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Aside from the above, liposomal nanoparticles exhibit more precise targeting abilities and stronger immune responses when exposed to external stimuli, such as hyperthermia, ultrasound, radiation, and magnetic fields, via encapsulation of specific agents [156,[212][213][214][215]. This is in accordance with the term, "Chemo Bomb", coined by Dr ten Hagen in 2010, to describe triggered drug release from liposomes [216].…”

Section: General Areas Of Improvementmentioning

confidence: 83%

Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks

2021

View full text Add to dashboard Cite

Cancer immunotherapy, a promising and widely applied mode of oncotherapy, makes use of immune stimulants and modulators to overcome the immune dysregulation present in cancer, and leverage the host’s immune capacity to eliminate tumors. Although some success has been seen in this field, toxicity and weak immune induction remain challenges. Liposomal nanosystems, previously used as targeting agents, are increasingly functioning as immunotherapeutic vehicles, with potential for delivery of contents, immune induction, and synergistic drug packaging. These systems are tailorable, multifunctional, and smart. Liposomes may deliver various immune reagents including cytokines, specific T-cell receptors, antibody fragments, and immune checkpoint inhibitors, and also present a promising platform upon which personalized medicine approaches can be built, especially with preclinical and clinical potentials of liposomes often being frustrated by inter- and intrapatient variation. In this review, we show the potential of liposomes in cancer immunotherapy, as well as the methods for synthesis and in vivo progression thereof. Both preclinical and clinical studies are included to comprehensively illuminate prospects and challenges for future research and application.

show abstract

“…The cellular toxicity study revealed that 80% of cells were found viable when the cells were treated with LipTS–GD–MAB. In addition to this, the LipTS–GD–MAB showed increased cellular internalization as compared to doxorubicin liposomes [ 55 ]. El-Senduny et al, 2021 prepared Azadiradione-loaded liposomes (AZD-lipo) for effective treatment of TNBC.…”

Section: Lipid-based Nanoparticles: a Versatile Drug Delivery Systemmentioning

confidence: 99%

Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy

Chaudhuri

Kumar

Shaik

et al. 2022

IJMS

View full text Add to dashboard Cite

Triple-negative breast cancer is considered the most aggressive type of breast cancer among women and the lack of expressed receptors has made treatment options substantially limited. Recently, various types of nanoparticles have emerged as a therapeutic option against TNBC, to elevate the therapeutic efficacy of the existing chemotherapeutics. Among the various nanoparticles, lipid-based nanoparticles (LNPs) viz. liposomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid nanocarriers, and lipid–polymer hybrid nanoparticles are developed for cancer treatment which is well confirmed and documented. LNPs include various therapeutic advantages as compared to conventional therapy and other nanoparticles, including increased loading capacity, enhanced temporal and thermal stability, decreased therapeutic dose and associated toxicity, and limited drug resistance. In addition to these, LNPs overcome physiological barriers which provide increased accumulation of therapeutics at the target site. Extensive efforts by the scientific community could make some of the liposomal formulations the clinical reality; however, the relatively high cost, problems in scaling up the formulations, and delivery in a more targetable fashion are some of the major issues that need to be addressed. In the present review, we have compiled the state of the art about different types of LNPs with the latest advances reported for the treatment of TNBC in recent years, along with their clinical status and toxicity in detail.

show abstract

ADAM 8 as a novel target for doxorubicin delivery to TNBC cells using magnetic thermosensitive liposomes

Cited by 23 publications

References 54 publications

Thermosensitive Liposomes Encapsulating Nedaplatin and Picoplatin Demonstrate Enhanced Cytotoxicity against Breast Cancer Cells

Thermosensitive Liposomes Encapsulating Nedaplatin and Picoplatin Demonstrate Enhanced Cytotoxicity against Breast Cancer Cells

Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks

Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy

Contact Info

Product

Resources

About